Retrospective review of 208 patients with leiomyosarcoma of the uterus: Prognostic indicators, surgical management, and adjuvant therapy

Gynecologic Oncology

Volumn 89, Issue 3, 2003, Pages 460-469

  Giuntoli II, Robert L ^a   Metzinger, Daniel S ^b   DiMarco, Connie S ^a   Cha, Stephen S ^a   Sloan, Jeff A ^a   Keeney, Gary L ^a   Gostout, Bobbie S ^a  

^a MAYO CLINIC   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Adjuvant chemotherapy; Adjuvant radiation therapy; Leiomyosarcoma; Oophorectomy; Retrospective study; Risk assessment index; Uterine neoplasms

Indexed keywords

DOXORUBICIN;

ADULT; ADVANCED CANCER; AGED; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CASE CONTROL STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; EVALUATION; FEMALE; FOLLOW UP; HEALTH CENTER; HUMAN; KAPLAN MEIER METHOD; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MEDICAL RECORD; MULTIVARIATE ANALYSIS; NONBIOLOGICAL MODEL; OUTCOMES RESEARCH; OVARIECTOMY; PATHOLOGIST; PREDICTION; PRESERVATION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; UTERUS SARCOMA;

EID: 0037498554     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00137-9     Document Type: Conference Paper

References (37)

1. Aaro L.A., Symmonds R.E., Dockerty M.B. Sarcoma of the uterus a clinical and pathologic study of 177 cases . Am J Obstet Gynecol. 94:1966;101-109.
2. Gard G.B., Mulvany N.J., Quinn M.A. Management of uterine leiomyosarcoma in Australia. Aust N Z J Obstet Gynaecol. 39:1999;93-98.
3. Major F.J., Blessing J.A., Silverberg S.G., Morrow C.P., Creasman W.T., Currie J.L., Yordan E., Brady M.F. Prognostic factors in early-stage uterine sarcoma a Gynecologic Oncology Group study . Cancer. 71:1993;1702-1709.
4. Van Dinh T., Woodruff J.D. Leiomyosarcoma of the uterus. Am J Obstet Gynecol. 144:1982;817-823.
5. Hannigan E.V., Gomez L.G. Uterine leiomyosarcoma. Am J Obstet Gynecol. 134:1979;557-564.
6. Mayerhofer K., Obermair A., Windbichler G., Petru E., Kaider A., Hefler L., Czerwenka K., Leodolter S., Kainz C. Leiomyosarcoma of the uterus a clinicopathologic multicenter study of 71 cases . Gynecol Oncol. 74:1999;196-201. (doi: 10.1006/gyno.1999-5436).
7. Peters W.A. III, Howard D.R., Andersen W.A., Figge D.C. Uterine smooth-muscle tumors of uncertain malignant potential. Obstet Gynecol. 83:1994;1015-1020.
8. Abu-Rustum N.R., Curtin J.P., Burt M., Jones W.B. Regression of uterine low-grade smooth-muscle tumors metastatic to the lung after oophorectomy. Obstet Gynecol. 89:1997;850-852.
9. Levenback C., Rubin S.C., McCormack P.M., Hoskins W.J., Atkinson E.N., Lewis J.L. Jr. Resection of pulmonary metastases from uterine sarcomas. Gynecol Oncol. 45:1992;202-205.
10. Annual report on the results of treatment of gynecologic cancer. Int J Gynecol Obstet. 28:1989;189-190.
11. Berchuck A., Rubin S.C., Hoskins W.J., Saigo P.E., Pierce V.K., Lewis J.L. Jr. Treatment of uterine leiomyosarcoma. Obstet Gynecol. 71:1988;845-850.
12. Gadducci A., Landoni F., Sartori E., Zola P., Maggino T., Lissoni A., Bazzurini L., Arisio R., Romagnolo C., Cristofani R. Uterine leiomyosarcoma analysis of treatment failures and survival . Gynecol Oncol. 62:1996;25-32. (doi: 10.1006/gyno. 1996-0815).
13. Larson B., Silfversward C., Nilsson B., Pettersson F. Prognostic factors in uterine leiomyosarcoma a clinical and histopathological study of 143 cases. The Radiumhemmet series 1936-1981 . Acta Oncol. 29:1990;185-191.
14. Nordal R.R., Kristensen G.B., Kaern J., Stenwig A.E., Pettersen E.O., Trope C.G. The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma. Acta Oncol. 34:1995;797-802.
15. Chen S.S. Propensity of retroperitoneal lymph node metastasis in patients with stage I sarcoma of the uterus. Gynecol Oncol. 32:1989;215-217.
16. Goff B.A., Rice L.W., Fleischhacker D., Muntz H.G., Falkenberry S.S., Nikrui N., Fuller A.F. Jr. Uterine leiomyosarcoma and endometrial stromal sarcoma lymph node metastases and sites of recurrence . Gynecol Oncol. 50:1993;105-109. (doi: 10.1006/gyno.1993-1172).
17. Omura G.A., Blessing J.A., Major F., Lifshitz S., Ehrlich C.E., Mangan C., Beecham J., Park R., Silverberg S. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas a Gynecologic Oncology Group study . J Clin Oncol. 3:1985;1240-1245.
18. Piver M.S., Lele S.B., Marchetti D.L., Emrich L.J. Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas. J Surg Oncol. 38:1988;233-239.
19. Muss H.B., Bundy B., DiSaia P.J., Homesley H.D., Fowler W.C. Jr, Creasman W., Yordan E. Treatment of recurrent or advanced uterine sarcoma a randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group) . Cancer. 55:1985;1648-1653.
20. Omura G.A., Major F.J., Blessing J.A., Sedlacek T.V., Thigpen J.T., Creasman W.T., Zaino R.J. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer. 52:1983;626-632.
21. Sutton G., Blessing J.A., Malfetano J.H. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus a Gynecologic Oncology Group study . Gynecol Oncol. 62:1996;226-229. (doi: 10.1006/gyno. 1996-0220).
22. Kalbfleisch J.D., Prentice R.L. The statistical analysis of failure time data. 1980;Wiley, New York.
23. Stevens J. Applied multivariate statistics for the social sciences. 3rd ed:1996;Lawrence Erlbaum Associates, Mahwah, NJ.
24. Liang K.Y., Self S.G., Bandeen-Roche K.J., Zeger S.L. Some recent developments for regression analysis of multivariate failure time data. Lifetime Data Anal. 1:1995;403-415.
25. Neter J., Wasserman W., Kutner M.H. Applied linear statistical models regression, analysis of variance, and experimental designs . 3rd ed:1990;300-305 Irwin, Homewood, IL.
26. McKinney W.P., Young M.J., Hartz A., Lee M.B. The inexact use of Fisher's exact test in six major medical journals. JAMA. 261:1989;3430-3433.
27. Kolassa J.E. A comparison of size and power calculations for the Wilcoxon statistic for ordered categorical data. Stat Med. 14:1995;1577-1581.
28. Nordal R.R., Thoresen S.O. Uterine sarcomas in Norway 1956-1992 incidence, survival and mortality . Eur J Cancer. 33:1997;907-911.
29. Olah K.S., Dunn J.A., Gee H. Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors the result of a retrospective study of 423 cases of uterine sarcoma . Br J Obstet Gynaecol. 99:1992;590-594.
30. O'Connor D.M., Norris H.J. Mitotically active leiomyomas of the uterus. Hum Pathol. 21:1990;223-227.
31. Hendrickson M.R., Kempson R.L. Pure mesenchymal neoplasms of the uterine corpus. Fox H. Haines and Taylor obstetrical and gynaecological pathology. 4th ed:1995;519-586 Churchill Livingstone, New York.
32. Bell S.W., Kempson R.L., Hendrickson M.R. Problematic uterine smooth muscle neoplasms a clinicopathologic study of 213 cases . Am J Surg Pathol. 18:1994;535-558.
33. Evans H.L., Chawla S.P., Simpson C., Finn K.P. Smooth muscle neoplasms of the uterus other than ordinary leiomyoma a study of 46 cases, with emphasis on diagnostic criteria and prognostic factors . Cancer. 62:1988;2239-2247.
34. Salazar O.M., Dunne M.E. The role of radiation therapy in the management of uterine sarcomas. Int J Radiat Oncol Biol Phys. 6:1980;899-902.
35. Zhai Y.L., Kobayashi Y., Mori A., Orii A., Nikaido T., Konishi I., Fujii S. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int J Gynecol Pathol. 18:1999;20-28.
36. Lantta M., Karkainen J., Walstrom T., Widholm O. Estradiol and progesterone receptors in gynecologic sarcomas. Acta Obstet Gynecol Scand. 63:1984;505-508.
37. Kattan M.W., Leung D.H., Brennan M.F. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 20:2002;791-796.